Last updated: 11/29/2018 19:40:27
Single-blind clinical study of the immunogenicity and reactogenicity of GSK Biologicals dTpa, pa vaccines and a Tdvaccine, given as a booster dose to healthy adults, from the age of 18 years onwards
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Single-blind clinical study of the immunogenicity and reactogenicity of GSK Biologicals dTpa, pa vaccines and a Tdvaccine, given as a booster dose to healthy adults, from the age of 18 years onwards
Trial description: Single-blind clinical study of the immunogenicity and reactogenicity of GSK Biologicals dTpa, pa vaccines and a Tdvaccine, given as a booster dose to healthy adults, from the age of 18 years onwards
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Burgess et al. Booster vaccination of healthy adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccines: immunogenicity five years post-vaccination. Abstract presented at the 10th annual conference on Vaccine Research, Baltimore MA, USA, 30 April - 02 May 2007.
Cheuvart B et al. (2004) Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 23 (3): 336–342.
McIntyre PB et al. (2004) High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 23 (3): 380-385.
McIntyre PB et al. (2009) Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: Immunogenicity 5 years post-vaccination. Vaccine 27 (7): 1062-1066.
Turnbull et al. (2000) A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 19 (6): 628-636.
Medical condition
Diphtheria, Tetanus, acellular pertussis
Product
Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
Collaborators
Not applicable
Study date(s)
June 1998 to November 1998
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1998-24-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website